首站-论文投稿智能助手
典型文献
High phosphorylated cyclin-dependent kinase 2 expression indicates poor prognosis of luminal androgen receptor triple-negative breast cancer
文献摘要:
Triple-negative breast cancer(TNBC)is a highly aggressive breast cancer subtype characterized by a lack of estrogen receptorα(ER)and progesterone receptor(PR)expression and the absence of HER2 overexpression or amplification.TNBC's high heterogeneity in both molecular and clinical features hinders the development of effective treatments;thus,further molecular classification of TNBC is still needed.
文献关键词:
作者姓名:
Zining Jin;Qingfu Zhang;Chunyu Wang;Shengli Wang;Lin Lin;Renlong Zou;Ge Sun;Kai Zeng;Baosheng Zhou;Yuxin Tong;Bo Chen;Yue Zhao
作者机构:
Department of Cell Biology,Key laboratory of Cell Biology,Ministry of Public Health,and Key laboratory of Medical Cell Biology,Ministry of Education,School of Life Sciences,China Medical University,Shenyang 110122,China;Department of Breast Surgery,the First Hospital of China Medical University,Shenyang 110001,China;Department of Pathology,the First Hospital and College of Basic Medical Sciences of China Medical University,Shenyang 110001,China
引用格式:
[1]Zining Jin;Qingfu Zhang;Chunyu Wang;Shengli Wang;Lin Lin;Renlong Zou;Ge Sun;Kai Zeng;Baosheng Zhou;Yuxin Tong;Bo Chen;Yue Zhao-.High phosphorylated cyclin-dependent kinase 2 expression indicates poor prognosis of luminal androgen receptor triple-negative breast cancer)[J].生物化学与生物物理学报(英文版),2022(07):1034-1038
A类:
B类:
High,phosphorylated,cyclin,dependent,kinase,indicates,poor,prognosis,luminal,androgen,receptor,triple,negative,breast,cancer,Triple,TNBC,highly,aggressive,subtype,characterized,by,lack,estrogen,progesterone,PR,absence,HER2,overexpression,amplification,heterogeneity,both,molecular,clinical,features,hinders,development,effective,treatments,thus,further,classification,still,needed
AB值:
0.708666
相似文献
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
Tingting Feng;Jing Wang;Kai Cheng;Qiqi Lu;Ru Zhao;Shiguan Wang;Qingyun Zhang;Luna Ge;Jihong Pan;Guanhua Song;Lin Wang-Department of Pathology,School of Basic Medical Sciences,Shandong University,Jinan 250012,China;Department of Pathology,The Fourth People's Hospital of Jinan,Jinan 250031,China;Department of PET-CT,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250002,China;The Second Hospital,Cheeloo College of Medicine,Shandong University Medical School,Jinan 250012,China;Biomedical Sciences College&Shandong Medicinal Biotechnology Centre,Key Lab for Biotech-Drugs of National Health Commission,Key Lab for Rare&Uncommon Diseases of Shandong Province,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Biochemistry and Molecular Biology,Shandong University School of Basic Medical Sciences,Jinan 250012,China;Institute of Basic Medicine,Shandong Academy of Medical Sciences,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Oncology,The First Affiliated Hospital of Shandong First Medical University,Jinan 250014,China
Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
Yi Xiao;Ding Ma;Yun-Song Yang;Fan Yang;Jia-Han Ding;Yue Gong;Lin Jiang;Li-Ping Ge;Song-Yang Wu;Qiang Yu;Qing Zhang;Francois Bertucci;Qiuzhuang Sun;Xin Hu;Da-Qiang Li;Zhi-Ming Shao;Yi-Zhou Jiang-Key Laboratory of Breast Cancer in Shanghai,Department of Breast Surgery,Fudan University Shanghai Cancer Center;Department of Oncology,Shanghai Medical College,Fudan University,Shanghai,China;Human Phenome Institute,Fudan University,Shanghai,China;Department of Pathology,University of Texas Southwestern Medical Center,Dallas,TX,USA;Predictive Oncology team,Centre de Recherche en Cancérologie de Marseille(CRCM),INSERM UMR1068,CNRS UMR725,Aix-Marseille Université,Institut Paoli-Calmettes,Marseille,France;Department of Industrial Systems Engineering and Management,National University of Singapore,Singapore,Singapore
Lenvatinib-and vadimezan-loaded synthetic high-density lipoprotein for combinational immunochemotherapy of metastatic triple-negative breast cancer
Chao Zheng;Wen Zhang;Jinming Wang;Yihui Zhai;Fengqin Xiong;Ying Cai;Xiang Gong;Binyu Zhu;Helen He Zhu;Hao Wang;Yaping Li;Pengcheng Zhang-China State Institute of Pharmaceutical Industry,Shanghai 201203,China;State Key Laboratory of Drug Research&Center of Pharmaceutics,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;State Key Laboratory of Oncogenes and Related Genes,Renji-Med-X Stem Cell Research Center,Department of Urology,Ren Ji Hospital,School of Medicine and School of Biomedical Engineering,Shanghai Jiao Tong University,Shanghai 200135,China;University of Chinese Academy of Sciences,Beijing 100049,China;Bohai Rim Advanced Research Institute for Drug Discovery,Yantai 264000,China;Yantai Key Laboratory of Nanomedicine&Advanced Preparations,Yantai Institute of Materia Medica,Yantai 264000,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。